At Medopad, we want to create a world where people can live longer. A world where the best minds continue doing their best work. A world where we can spend more time with our loved ones. Our technology takes a modular approach which means we cover a wide variety of disease areas to deliver better and more personalised care by transforming the way patients and data interact with clinicians. Our Artificial Intelligence division uses data collected through our platform to generate predictive insights which will be able to detect life threatening medical conditions.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

GOLDENBIOTECH'S NEW DRUG ANTROQUINONOL RECEIVES FDA APPROVAL ON COVID-19 PHASE 2 CLINICAL TRIAL IN USA

Golden Biotechnology Corp. | July 02, 2020

news image

Golden Biotechnology Corp. (GoldenBiotech, 4132.TWO), a leading Taiwanese biopharmaceutical company, announced that the FDA approved its investigational new drug (IND) application for a Phase II clinical trial of Antroquinonol (Hocena®) on COVID-19 patients in USA. GoldenBiotech has also applied for the US BARDA (Biomedical Advanced Research and Development Administration) CoronaWatch meeting. Future developmental planning of Antroquinonol in COVID-19 include joining the COVID-19 Candidate a...

Read More

MEDICAL

ASPECT BIOSYSTEMS ANNOUNCES PARTNERSHIP WITH JDRF TO ADVANCE DEVELOPMENT OF A BIOENGINEERED TISSUE THERAPEUTIC TO TREAT TYPE 1 DIABETES

Aspect Biosystems | April 07, 2022

news image

Aspect Biosystems ("Aspect"), a biotechnology company developing bioengineered tissue therapeutics to transform how we treat disease, is pleased to announce a partnership with JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization. The JDRF-Aspect partnership supports Aspect's focus on developing a bioengineered tissue therapeutic for type 1 diabetes that will provide insulin independence and control of blood sugar without the need for chro...

Read More

MEDTECH

COSMOSID LAUNCHES ACCURATE AND EASY FUNCTIONAL MICROBIOME ANALYSIS WITH NEW SOFTWARE PLATFORM, COSMOSID-HUB: MICROBIOME

CosmosID | September 27, 2021

news image

A complete analysis of the microbiome should combine taxonomic profiling ("who is there?") with functional characterization ("what are they doing?") to discover the capabilities of an entire community of microorganisms. But research teams often require specialized training and extensive computational infrastructure to establish an in-house suite of tools for processing shotgun metagenomic data – and even with the right know-how, the processing can be both time-consuming...

Read More

MEDICAL

SLINGSHOT BIOSCIENCES, INC. PARTNERS WITH CAMBRIDGE BIOSCIENCE TO DISTRIBUTE SYNTHETIC CELLS THROUGHOUT UNITED KINGDOM AND IRELAND

Slingshot | June 16, 2022

news image

SLINGSHOT BIOSCIENCES, INC. the makers of synthetic cells that bring consistent precision and accurate control to replace inconsistent blood and tissue controls for use in flow cytometry and other biotech markets, today announced they have extended their distribution channel through a new agreement with Cambridge Bioscience, a UK-based specialist distributor of life science research tools. The agreement entitles Cambridge Bioscience to the right to distribute and resell Slingshot ...

Read More
news image

GOLDENBIOTECH'S NEW DRUG ANTROQUINONOL RECEIVES FDA APPROVAL ON COVID-19 PHASE 2 CLINICAL TRIAL IN USA

Golden Biotechnology Corp. | July 02, 2020

Golden Biotechnology Corp. (GoldenBiotech, 4132.TWO), a leading Taiwanese biopharmaceutical company, announced that the FDA approved its investigational new drug (IND) application for a Phase II clinical trial of Antroquinonol (Hocena®) on COVID-19 patients in USA. GoldenBiotech has also applied for the US BARDA (Biomedical Advanced Research and Development Administration) CoronaWatch meeting. Future developmental planning of Antroquinonol in COVID-19 include joining the COVID-19 Candidate a...

Read More
news image

MEDICAL

ASPECT BIOSYSTEMS ANNOUNCES PARTNERSHIP WITH JDRF TO ADVANCE DEVELOPMENT OF A BIOENGINEERED TISSUE THERAPEUTIC TO TREAT TYPE 1 DIABETES

Aspect Biosystems | April 07, 2022

Aspect Biosystems ("Aspect"), a biotechnology company developing bioengineered tissue therapeutics to transform how we treat disease, is pleased to announce a partnership with JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization. The JDRF-Aspect partnership supports Aspect's focus on developing a bioengineered tissue therapeutic for type 1 diabetes that will provide insulin independence and control of blood sugar without the need for chro...

Read More
news image

MEDTECH

COSMOSID LAUNCHES ACCURATE AND EASY FUNCTIONAL MICROBIOME ANALYSIS WITH NEW SOFTWARE PLATFORM, COSMOSID-HUB: MICROBIOME

CosmosID | September 27, 2021

A complete analysis of the microbiome should combine taxonomic profiling ("who is there?") with functional characterization ("what are they doing?") to discover the capabilities of an entire community of microorganisms. But research teams often require specialized training and extensive computational infrastructure to establish an in-house suite of tools for processing shotgun metagenomic data – and even with the right know-how, the processing can be both time-consuming...

Read More
news image

MEDICAL

SLINGSHOT BIOSCIENCES, INC. PARTNERS WITH CAMBRIDGE BIOSCIENCE TO DISTRIBUTE SYNTHETIC CELLS THROUGHOUT UNITED KINGDOM AND IRELAND

Slingshot | June 16, 2022

SLINGSHOT BIOSCIENCES, INC. the makers of synthetic cells that bring consistent precision and accurate control to replace inconsistent blood and tissue controls for use in flow cytometry and other biotech markets, today announced they have extended their distribution channel through a new agreement with Cambridge Bioscience, a UK-based specialist distributor of life science research tools. The agreement entitles Cambridge Bioscience to the right to distribute and resell Slingshot ...

Read More